Watch the Facebook Live Replay from the 2025 American Society of Hematology (ASH) Meeting

Описание: What Myeloma Patients and Care Partners Need to Know from ASH 2025 | Facebook Live Replay

The International Myeloma Foundation (IMF) went live from the American Society of Hematology (ASH) Annual Meeting in Orlando to help patients and care partners make sense of the latest research in multiple myeloma.

Hosted by Dr. Joseph Mikhael, IMF Chief Medical Officer, the session brought together myeloma support group leaders and patients from across the U.S. (and online) to ask real-world questions about new treatments, side effects, vaccines, access to care, and what all this science actually means for daily life with myeloma.

Throughout the conversation, one theme kept coming up: hope—grounded in real data, real progress, and real people.

Questions Answered in this Video:
0:00 - Introductions
15:55: Are we getting better at managing cytokine release syndrome (CRS) with new immune therapies like CAR T and bispecific antibodies?
Can blood counts like the absolute lymphocyte count (ALC) help predict neurological toxicity from CAR T, and are we getting closer to preventing these brain and nerve side effects?
With measles outbreaks across the country, how worried should myeloma patients be about infections, and what does this mean for vaccines like the measles (MMR) shot?
With so many new studies and treatments presented at ASH, how can I be sure my doctor knows about them and uses this information to guide my myeloma care?
Many patients still don’t have access to the latest myeloma treatments due to racial, geographic, and socioeconomic inequalities. How can we address these healthcare disparities?
New CAR T constructs like anito-cel use a special binding domain and show zero delayed neurotoxicities in early data. Could this kind of design be the future of safer CAR T therapy?
In vivo CAR T sounds like science fiction turned real—how does it work, and what might it mean for how patients receive CAR T therapy in the future?
For patients with smoldering multiple myeloma, especially those at higher risk or at different time points since diagnosis, how should they think about early treatment with daratumumab versus watchful waiting or full myeloma therapy?
Among all the therapies in the myeloma pipeline, which ones are you most excited about to help patients, and why?

Don't miss this in-depth Q&A with Dr. Mikhael and be sure to submit your own questions using #AskTheIMF on Facebook, Instagram, or X. Learn more at myeloma.org. Like, Comment, and Subscribe for weekly updates on myeloma research, treatment, and patient support. Have a question that needs more personalized support?

Call us! We’re here for you. The IMF’s InfoLine is available to answer your myeloma-related questions and concerns. Call us at 1-818-487-7455, email us at [email protected], or schedule your call at a time that works best for you at www.myeloma.org/infoline.

Watch the replay now—you won’t want to miss it!
#imfash25 #ash25
_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
X/Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/52...

Category
Nonprofits & Activism
License
Standard YouTube License

The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.